Matching articles for "mResvia"
Issue 1754 · May 11, 2026 Free
In Brief: RSV Vaccine (Arexvy) for Ages 18-49

The FDA has expanded the licensed use of the recombinant respiratory syncytial virus (RSV) vaccine Arexvy (GSK) to include adults 18-49 years old. Arexvy and the two other available RSV vaccines, Abrysvo and…

Med Lett Drugs Ther. 2026 May 11; 68(1754):77-8 doi:10.58347/tml.2026.1754d
The FDA has expanded the licensed use of the recombinant respiratory syncytial virus (RSV) vaccine Arexvy (GSK) to include adults 18-49 years old. Arexvy and the two other available RSV vaccines, Abrysvo and mResvia , are now all licensed for prevention of RSV lower respiratory tract disease in persons ≥60 years old and in those 18-59 years old who are at increased risk of lower respiratory tract disease caused by RSV. Abrysvo is also licensed for use in pregnant women at 32-36 weeks' gestation to prevent RSV-associated lower respiratory tract disease in their infants from birth to 6 months.
Issue 1722 · February 17, 2025 Free
In Brief: New Warning for the RSV Vaccines Arexvy and Abrysvo

The FDA has required a new warning in the labels of the recombinant respiratory syncytial virus (RSV) vaccines Arexvy (GSK) and Abrysvo (Pfizer) about an increased risk of Guillain-Barré syndrome (GBS) within…

Med Lett Drugs Ther. 2025 Feb 17; 67(1722):31-2 doi:10.58347/tml.2025.1722d
The FDA has required a new warning in the labels of the recombinant respiratory syncytial virus (RSV) vaccines Arexvy (GSK) and Abrysvo (Pfizer) about an increased risk of Guillain-Barré syndrome (GBS) within 42 days of administration of either vaccine. Both vaccines are FDA-approved to prevent lower respiratory tract disease (LRTD) caused by RSV in adults. Abrysvo is also approved for use in pregnant women at 32-36 weeks' gestation to prevent RSV-associated LRTD in their infants from birth through 6 months of age.
Issue 1713 · October 14, 2024 Free
A New RSV Vaccine (mResvia) for Adults ≥60 Years Old

TThe FDA has licensed mResvia (Moderna), an mRNA respiratory syncytial virus (RSV) vaccine, for prevention of lower respiratory tract disease (LRTD) caused by RSV in adults ≥60 years old. It is the first…

Med Lett Drugs Ther. 2024 Oct 14; 66(1713):166-8 doi:10.58347/tml.2024.1713d
TThe FDA has licensed mResvia (Moderna), an mRNA respiratory syncytial virus (RSV) vaccine, for prevention of lower respiratory tract disease (LRTD) caused by RSV in adults ≥60 years old. It is the first mRNA vaccine to be licensed in the US for this indication. Two recombinant RSV vaccines, Arexvy and Abrysvo , are also available for prevention of RSV LRTD. Arexvy is approved for use in adults ≥50 years old. Abrysvo is approved for use in adults ≥60 years old and in pregnant women to prevent RSV LRTD in their infants.
Issue 1707 · July 22, 2024 Free
In Brief: RSV Vaccine (Arexvy) for Ages 50-59

The recombinant respiratory syncytial virus (RSV) vaccine Arexvy (GSK) has now received FDA approval for use in adults 50-59 years old who are at increased risk for lower respiratory tract disease (LRTD)…

Med Lett Drugs Ther. 2024 Jul 22; 66(1707):113-4 doi:10.58347/tml.2024.1707a
The recombinant respiratory syncytial virus (RSV) vaccine Arexvy (GSK) has now received FDA approval for use in adults 50-59 years old who are at increased risk for lower respiratory tract disease (LRTD) caused by RSV. It was previously approved only for adults ≥60 years old. Two other RSV vaccines have received FDA approval: Abrysvo , a recombinant vaccine that is licensed for use in adults ≥60 years old and in pregnant women at 32-36 weeks' gestation to prevent RSV-associated LRTD in their infants, and mResvia , an mRNA vaccine recently licensed for use in adults ≥60 years old that will be available for the 2024-25 RSV season.